Viveve Medical, Inc. (VIVE) News
Follow Viveve Medical, Inc. (VIVE) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Vivesto reports positive Paccal Vet topline in 21-cat study
Vivesto AB said preliminary topline data showed anti-tumor activity and an MTD higher than expected in its 21-cat Paccal Vet dose-finding study. Final analyzed results are expected in Q4 2026.
EQUITY | Sep 17, 2026, 08:09 AM UTC
L
Vivesto Says Topline Results For Paccal Vet 'Positive'
Vivesto AB OMXSTO:VIVE
NEWS | Sep 15, 2026, 11:55 AM UTC
L
Vivesto AB Reports Positive Topline Data for Paccal Vet in Dogs
Vivesto reported positive topline results in 26 dogs with Stage I—II splenic hemangiosarcoma post-splenectomy, showing median overall survival of 135 days with Paccal Vet. Data support moving to a pivotal study; four dog
NEWS | Sep 15, 2026, 11:45 AM UTC
L
Vivesto’s positive dog topline results support continued development and strengthen partnering prospects for Paccal Vet
Solna, Sweden, September 15, 2026 — Vivesto AB, an oncology-focused development company, today announced positive topline results from its open label clinical pilot study evaluating Paccal Vet in dogs with splenic hemang
NEWS | Sep 15, 2026, 11:45 AM UTC